David McIntosh: UK Plasma Action – a Founder’s Reflections
David McIntosh, Founder and Chair of United Plasma Action, shared a post on LinkedIn:
”UK Plasma Action – a Founder’s Reflections
The UKPA campaign, launched in June 2019, was aimed at the discontinuation of a 23 year-old ban on the pharmaceutical use of UK donors’ plasma.
Much has happened since then and much good work has been done. Our donations are once again contributing to the manufacture of some vital plasma-derived medicines. The worst of the waste has been halted.
However, it seems appropriate, seven years on, to pause and reflect on the progress made so far – and the extent to which more action is still required.
The 20th Century fears about alleged risks of Variant Creutzfeldt Jakob disease in this context have now finally been dispelled.
However, the full Regulatory consequences and Healthcare gains from this welcome development are yet to be realised.
There is unfinished business here…….”
Other posts featuring David McIntosh on Hemostasis Today.
-
Aug 3, 2026, 15:33Christina Crossette-Thambiah: Scientific Excellence and Mentorship at ISTH 2026
-
Aug 3, 2026, 15:22Connie Montgomery: Why Global Support is Essential for the HFA Black Voices Initiative
-
Aug 3, 2026, 15:18Ifeanyichukwu Ifechidere: The DOAC Monitoring Masterclass
-
Aug 3, 2026, 14:49Ney Carter Borges: Targeting the Gut Microbiome to Prevent Atrial Fibrillation
-
Aug 3, 2026, 13:42Immune Thrombocytopenia: Moving Beyond Platelet Counts Toward Durable Remission
-
Aug 3, 2026, 13:28Aboo Shama Khan: Pulmonary Embolism – A Medical Emergency Every Nurse Must Recognize
-
Aug 3, 2026, 13:08Ashwin Patel: Evaluating Red Cell Function Post-Treatment in SCD Patients
-
Aug 3, 2026, 13:03Mohamed El Belghiti Alaoui: The Promise of AAV Gene Therapy in Hemophilia A
-
Aug 3, 2026, 12:44Replaying the CSL Symposium on Gene Therapy Durability in Haemophilia – EAHAD